2018
Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions
Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.Peer-Reviewed Original ResearchRBC transfusion independenceHMA initiationTransfusion independenceTransfusion dependenceLR-MDSClinical trial dataHypomethylating agentTransfusion statusMedian timeMedian TI durationCox modelContinuous Medicare Parts ATrial dataRed blood cell transfusionDiagnosis of MDSRBC transfusion dependenceSubset of ptsBlood cell transfusionEnd Results-MedicareErythropoiesis-stimulating agentsHigh-risk diseaseMultivariate Cox modelTreatment of MDSEnd of studyTI duration
2016
Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS
Steensma D, Scott B, Ma X, Fliss A, Kiselev P, Swern A, Sugrue M. Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS. Blood 2016, 128: 4768. DOI: 10.1182/blood.v128.22.4768.4768.Peer-Reviewed Original ResearchAbsolute neutrophil countMedian absolute neutrophil countSequence of therapyMedian platelet countFirst therapyMedian ageMyelodysplastic syndromeMedian Hb levelPlatelet countHb levelsTreatment groupsCelgene CorporationSecond therapyFirst treatmentTreatment of MDSHigher absolute neutrophil countCommon initial therapyCurrent care patternsLower median hemoglobinUndertreatment of patientsAvailable therapeutic agentsHigher platelet countsClinical Modification codingSimilar Hb levelsThird therapy